AZ1508
Code | Size | Price |
---|
TAR-T18310-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T18310-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
AZ1508 is a drug-linker conjugates for ADC for the treatment of breast and stomach cancer, and the drug is a tubulin inhibitor[1].
CAS:
1817736-04-1
Molecular Weight:
1092.39
Purity:
0.98
SMILES:
[C@H](C[C@@H](N(C([C@@H](NC(=O)[C@@H]1N(C)CC[C@@H](C)C1)[C@H](CC)C)=O)CC)C(C)C)(OC(C)=O)C2=NC(C(N[C@@H](CC3=CC=C(NC([C@@H](NC(CCCCCN4C(=O)C=CC4=O)=O)CCCCN)=O)C=C3)C[C@@H](C(O)=O)C)=O)=CS2
References
Samantha Congreve, et al. Antibody drug conjugates (ADC) Current status and mapping of ADC:s in clinical programs. Uppsala Universitet.